11250 EL CAMINO REAL, SUITE 100, SAN DIEGO, CA
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CFO Departure - Kaitlyn Arsenault Steps Down with $450,000 Severance
Investor Presentation
Skye Bioscience Enters Non-Exclusive Agreement with Halozyme for Drug Delivery
Financial Results, Press Release
Reports Topline CBeyond Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Reports Second Quarter 2025 Financial Results and Business Update
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Definitive Information Statement
Preliminary Information Statement
Definitive Merger Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Amended Schedule 13D - Ownership Report